NCT02609737View on ClinicalTrials.gov

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 13, 2015

Primary Completion Date

December 10, 2020

Study Completion Date

December 10, 2020

Conditions
Neuroendocrine Tumors
Interventions
DEVICE

PET/CT Imaging

RADIATION

68Ga-DOTA-JR11

RADIATION

177Lu-DOTA-JR11

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02609737 - Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter